News & Updates
Showing Multidisciplinary articles
Showing

Seladelpar delivers improvements in cholestatic biomarkers, pruritus in PBC patients
Treatment with seladelpar for up to 2 years improves cholestatic biomarkers and pruritus in patients with primary biliary cholangitis (PBC), with no serious safety concerns noted with long-term use, as shown by interim results of the ASSURE study.
Seladelpar delivers improvements in cholestatic biomarkers, pruritus in PBC patients
09 May 2026
Balanced diet helps ease depressive symptoms
Higher consumption of plant-based food and a diet of egg, seafood, poultry, and meat appear to reduce the likelihood of depressive symptoms in adults, reports a China study.
Balanced diet helps ease depressive symptoms
08 May 2026
Naltrexone–bupropion a safe weight-loss treatment for persons with obesity, depression
The extended-release combination of naltrexone and bupropion (NB-ER) may be used as safe and effective treatment for weight reduction among individuals with overweight/obesity and mild to moderate symptoms of depression, suggests a study.
Naltrexone–bupropion a safe weight-loss treatment for persons with obesity, depression
08 May 2026
Esketamine, rTMS and ECT: Which is more cost-effective in treatment-resistant depression?
Esketamine is more cost-effective than transcranial magnetic stimulation (rTMS) and electroconvulÂsive therapy (ECT), but not when compared with other commonly used third-line treatments for treatment-resistant depression (TRD) in Hong Kong, a multi-armed modelling study has shown.





